The Drug Regulatory Authority of Pakistan (DRAP) has approved the registration of two more drugs – Actemra (Roshe) Tocilizumab and US medicine Remedesivir – on a priority basis.
According to details, DRAP has issued an official circular to concerned agencies and organisations.
The federal government has warned that strict action will be taken against overpricing or black marketing of life-saving drugs used by Covid-19 patients.
Special Assistant to the Prime Minister on National Health Services Dr Zafar Mirza said the DRAP has been ordered to ensure the availability of medicines used to control the virus.
He said Tocilizumab (Actemra) and Remedesivir injections used for coronavirus patients will be distributed to critically ill patients.
The special assistant said the public should inform DRAP on 0800-03727 if they have been overcharged for injections. Earlier DRAP approved Pakistan’s First COVID-19 Testing Kit.
Federal Minister for Science and Technology Chaudhry Fawad Hussain has announced that Drug Regulatory Authority of Pakistan (DRAP) has approved country’s first COVID testing kit.
The number of positive coronavirus cases in Pakistan has soared to 148925 with 2839 recorded deaths.
According to the latest figures by the National Command and Operation Center (NCOC), 2028 persons have been tested positive for COVID-19 in 24 hours. However, 55 more deaths reported in the country.